DOCSLIB.ORG

SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SPECIALTY MEDICATIONS Available Through Accredo Health Group, Inc., Medco’S Specialty Pharmacy Call Toll-Free (800) 803-2523, 8:00 A.M SPECIALTY MEDICATIONS available through Accredo Health Group, Inc., Medco’s specialty pharmacy Call toll-free (800) 803-2523, 8:00 a.m. to 8:00 p.m., eastern time, Monday through Friday, to confirm that your medication is covered. Effective as of July 1, 2011 Abraxane® (paclitaxel protein-bound particles) Berinert® (C 1 esterase inhibitor [human])* (PA) (QD) Actemra ™ (tocilizumab) (PA) Betaseron® (interferon beta-1b) (PA) Actimmune® (interferon gamma-1b) (PA) Botox® (botulinum toxin type A) (PA) Adagen® (pegademase bovine) Carbaglu ™ (carglumic acid) Adcirca® (tadalafil) (ST) (QD) Carimune® NF (immune globulin intravenous [human]) (PA) Advate® (antihemophilic factor [recombinant]) (CPA) Cerezyme® (imiglucerase) (CPA) (ST) Afinitor® (everolimus) (PA) (QD) Cimzia® (certolizumab pegol) (ST) Aldurazyme® (laronidase) (CPA) Copaxone® (glatiramer acetate) (PA) Alphanate® (antihemophilic factor [human]) (CPA) Copegus® (ribavirin) (ST) AlphaNine® SD (coagulation factor IX [human]) (CPA) Corifact® (factor XIII [human]) (CPA) Amevive® (alefacept) (PA) Cystadane® (betaine) Ampyra ™ (dalfampridine) (PA) CytoGam® (cytomegalovirus immune globulin Apokyn® (apomorphine hydrochloride) (PA) (QD) intravenous [human])* (CPA) Aralast® (alpha[1]-proteinase inhibitor [human]) Cytovene® IV (ganciclovir sodium)* Aranesp® (darbepoetin alfa) (PA) Dacogen® (decitabine) Arcalyst® (rilonacept) (PA) (QD) Dysport® (abobotulinumtoxinA) (PA) Arixtra® (fondaparinux sodium)* Egrifta ™ (tesamorelin) (PA) Arranon® (nelarabine) Elaprase® (idursulfase) (CPA) Arzerra® (ofatumumab) Eligard® (leuprolide acetate) ATryn® (antithrombin [recombinant])* Enbrel® (etanercept) (PA) Avastin® (bevacizumab) (PA) (QD) Enoxaparin sodium (GENERIC )* Avonex® (interferon beta-1a) (PA) Epogen® (epoetin alfa) (PA) Bebulin® VH (factor IX complex) (CPA) Epoprostenol sodium (GENERIC ) (ST) BeneFIX® (coagulation factor IX [recombinant]) (CPA) Erbitux® (cetuximab) (PA) (QD) Benlysta® (belimumab) Euflexxa® (sodium hyaluronate) (QD) *Specialty drug is available through Accredo Health Group, Inc., Medco’s specialty pharmacy, for long-term use and through participating retail pharmacies for short-term/emergency use. The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program. The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program. The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program. The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program. Exjade® (deferasirox) Hyalgan® (sodium hyaluronate) (QD) Extavia® (interferon beta-1b) (PA) Hycamtin® capsules (topotecan) Fabrazyme® (agalsidase beta) (CPA) HyperRho® S/D (Rh o[D] immune globulin [human])* Feiba® VH (anti-inhibitor coagulant complex) (CPA) Incivek ™ (telaprevir) Firmagon ® (degarelix) Increlex® (mecasermin [rDNA origin]) (PA) Flebogamma® (immune globulin [human]) (PA) Infergen® (interferon alfacon-1) (PA) Flolan® (epoprostenol sodium) (ST) Innohep® (tinzaparin sodium)* Folotyn ™ (pralatrexate) Intron® A (interferon alfa-2b) (PA) Forteo® (teriparatide [rDNA origin]) (ST) Iprivask® (desirudin)* Fragmin® (dalteparin sodium)* Istodax® (romidepsin) (PA) (QD) Fuzeon® (enfuvirtide) Ixempra® (ixabepilone) GamaSTAN ® S/D (immune globulin [human]) * Jevtana® (cabazitaxel) (PA) (QD) Gammagard® Liquid (immune globulin [human]) (PA) Kineret® (anakinra) (PA) Gammagard® S/D (immune globulin [human]) (PA) Koate®-DVI (antihemophilic factor [human]) (CPA) Gammaplex® (immune globulin [human]) (PA) Kogenate® FS (antihemophilic factor [recombinant]) (CPA) Gamunex® (immune globulin [human]) (PA) Krystexxa ™ (pegloticase) (ST) (QD) Ganciclovir (GENERIC )* Kuvan® (sapropterin dihydrochloride) (PA) Genotropin® (somatropin [rDNA origin]) (PA) Letairis® (ambrisentan) (ST) Gilenya ™ (fingolimod) (PA) Leukine® (sargramostim) (PA) Glassia ™ (alpha [1]-proteinase inhibitor [human]) Leuprolide acetate (GENERIC )* Gleevec® (imatinib mesylate) (PA) (QD) Lovenox® (enoxaparin sodium)* Halaven ™ (eribulin mesylate) Lucentis® (ranibizumab) Helixate® FS (antihemophilic factor [recombinant]) (CPA) Lumizyme ™ (alglucosidase alfa) (CPA) Hemofil® M (antihemophilic factor [human]) (CPA) Lupron Depot® (leuprolide acetate) Herceptin® (trastuzumab) (ST) Lupron Depot-PED® (leuprolide acetate) Hizentra ™ (immune globulin subcutaneous [human]) (PA) Luveris® (lutropin alfa) H.P. Acthar® Gel (corticotropin)* (PA) Macugen® (pegaptanib sodium injection) Humate-P® (antihemophilic factor/von Willebrand factor complex [human]) (CPA) Makena ™ (hydroxyprogesterone caproate) (CPA) Humatrope® (somatropin [rDNA origin]) (PA) MICRhoGAM® (Rh o[D] immune globulin [human])* Humira® (adalimumab) (PA) Mitoxantrone HCl (GENERIC ) *Specialty drug is available through Accredo Health Group, Inc., Medco’s specialty pharmacy, for long-term use and through participating retail pharmacies for short-term/emergency use. The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program. The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program. The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program. The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program. Monoclate-P® (antihemophilic factor [human]) (CPA) Procrit® (epoetin alfa) (PA) Mononine® (coagulation factor IX [human]) (CPA) Profilnine® SD (factor IX complex [human]) (CPA) Mozobil® (plerixafor)* (QD) Proleukin® (aldesleukin)* Myobloc® (botulinum toxin type B) (PA) Prolia ™ (denosumab) (PA) (QD) Myozyme® (alglucosidase alfa) (CPA) Promacta® (eltrombopag) (PA) Naglazyme® (galsulfase) (CPA) Pulmozyme® (dornase alfa) Neulasta® (pegfilgrastim)* (PA) Qutenza® (capsaicin) Neumega® (oprelvekin) (PA) Rebetol® (ribavirin) (ST) Neupogen® (filgrastim) (PA) Rebif® (interferon beta-1a) (PA) Nexavar® (sorafenib) (PA) (QD) Recombinate ™ (antihemophilic factor [recombinant]) (CPA) (PA) Norditropin® (somatropin [rDNA origin]) (PA) Remicade® (infliximab) Remodulin® (treprostinil sodium) (ST) Norditropin/Nordiflex® (somatropin [rDNA origin]) (PA) Retisert® (fluocinolone acetonide) (PA) (QD) Novantrone® (mitoxantrone HCl) (PA) Revatio® injection (sildenafil citrate) (ST) (QD) NovoSeven® RT (coagulation factor VIIa [recombinant]) (CPA) Revatio® tablets (sildenafil citrate) (ST) (QD) Nplate® (romiplostim)* (PA) Revlimid® (lenalidomide) (PA) (QD) Nutropin® (somatropin [rDNA origin]) (PA) RhoGAM® (RH o[D] immune globulin [human])* Nutropin AQ® (somatropin [rDNA origin]) (PA) Rhophylac® (RH o[D] immune globulin intravenous Octagam® (immune globulin intravenous [human]) (PA) [human])* Octreotide acetate (GENERIC ) RiaSTAP® (fibrinogen)* Oforta ™ (fludarabine) RibaPak® (GENERIC ) Omnitrope® (somatropin) (PA) Ribasphere® (GENERIC ) Orencia® (abatacept) (PA) Ribavirin (GENERIC ) Orfadin® (nitisinone) Rituxan® (rituximab) (PA) OrthoVisc® (hyaluronate sodium) (QD) Sabril® (vigabatrin)* Ozurdex ™ (dexamethasone) Saizen® (somatropin [rDNA origin]) (PA) Pegasys® (peginterferon alfa-2a) (PA) Samsca® (tolvaptan)* PEG-Intron® (peginterferon alfa-2b) (PA) Sandostatin® (octreotide acetate) PEG-Intron® Redipen® (peginterferon alfa-2b) (PA) Sandostatin LAR® (octreotide/IM) Prialt® (ziconotide) Sensipar® (cinacalcet hydrochloride) (PA) Privigen® (immune globulin intravenous [human]) (PA) Serostim® (somatropin [rDNA origin]) (PA) *Specialty drug is available through Accredo Health Group, Inc., Medco’s specialty pharmacy, for long-term use and through participating retail pharmacies for short-term/emergency use. The symbol [PA] next to a drug name indicates that this medication is subject to the Prior Authorization Program. The symbol [ST] next to a drug name indicates that this medication is subject to the Step Therapy Program. The symbol [QD] next to a drug name indicates that this medication is subject to the Quantity Duration Program. The symbol [CPA] next to a drug name indicates that this medication is subject to the Client Prior Authorization Program. Simponi ™ (golimumab) (ST) Vectibix® (panitumumab) (PA) Soliris® (eculizumab) (PA) Velcade® (bortezomib) Somatuline Depot® (lanreotide) Veletri® (epoprostenol sodium) Somavert® (pegvisomant) (PA) Ventavis® (iloprost) (ST) (QD) Spryce l® (dasatinib) (PA) (QD) Victrelis ™ (boceprevir) Stelara ™ (ustekinumab) (PA) (QD) Vidaza® (azacitidine) (PA) (QD) Stimate® (desmopressin acetate) Vivitrol® (naltrexone) Supartz® (sodium hyaluronate) (QD) Votrient® (pazopanib) (PA) (QD) Supprelin® LA (histrelin acetate) Vpriv ™ (velaglucerase alfa) (PA) Sutent® capsules (sunitinib malate) (PA) (QD) Wilate® (von Willebrand factor/coagulation factor VIII complex [human]) (CPA) Sylatron ™ (peginterferon alfa-2b) (PA) WinRho SDF® (Rh o[D] immune globulin intravenous Synagis® (palivizumab) (PA) (QD) [human])* Synvisc® (hylan G-F 20) (QD) Xeloda® (capecitabine)* Tarceva® (erlotinib) (PA) (QD) Xenazine® (tetrabenazine) (PA) (QD) Tasigna® (nilotinib) (PA) (QD) Xeomin® (incobotulinumtoxinA) (PA) Temodar® capsules (temozolomide) (PA) Xgeva ™ (denosumab) Temodar® injection (temozolomide) (PA) Xiaflex ™ (collagenase clostridium histolyticum) Tev-Tropin® (somatropin [rDNA origin]) (PA) Xolair® (omalizumab) (PA) (QD) Thalomid® (thalidomide) (PA) Xyntha® (antihemophilic factor [recombinant]) (CPA) Tobi® (tobramycin) (ST) (QD) Yervoy ™ (ipilimumab)
Load more

Recommended publications
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • Package Leaflet: Information for the User Innohep® 10,000 IU/Ml Solution for Injection Tinzaparin Sodium
    Package leaflet: Information for the user innohep® 10,000 IU/ml solution for injection tinzaparin sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet innohep 10,000 IU/ml will be called innohep. What is in this leaflet 1. What innohep® is and what it is used for 2. What you need to know before you use innohep® 3. How to use innohep® 4. Possible side effects 5. How to store innohep® 6. Contents of the pack and other information 1. What innohep® is and what it is used for innohep is a type of heparin – a low molecular weight heparin – and belongs to a group of medicines called anticoagulants; these medicines affect how your blood clots. innohep prevents clotting, allowing normal blood flow through the arteries and veins. innohep is used to: Prevent blood clots in adults before and after an operation. Prevent blood clots in adults who have an increased risk of blood clots e.g. due to an acute illness with limited mobility. Prevent blood clots being formed in haemodialysis equipment in patients undergoing haemodialysis or haemofiltration.
    [Show full text]
  • Hemosil ® Liquid Anti-Xa
    H E M O S I L® LIQUID ANTI-XA Measuring heparin and apixaban: Simple, fast, 24/7 • Liquid formulation, ready-to-use • One-stage, chromogenic anti-Xa assay • Universal calibration for unfractionated heparin (UFH) and low molecular weight heparin (LMWH) • Drug specific calibrators and controls for measurement of apixaban Measuring heparin and apixaban Unfractionated and low molecular weight heparin Heparin is a highly sulfated polysaccharide Laboratory monitoring is extremely important to characterized by a wide molecular weight range and assess the appropriate level of anticoagulation in potent anticoagulant activity. It exists either as UFH patients receiving UFH. Anti-Xa is recommended for or as depolymerized LMWH. UFH and LMWH have measuring both UFH and LMWH. a rapid anticoagulant effect and are used in the prevention and treatment of venous thrombosis and Anti-Xa testing for measuring UFH helps improve acute coronary syndrome. quality of care and patient experience while reducing costs, when compared with APTT testing.1 UFH and LMWH anticoagulant activity occurs when The advantages include: a complex with antithrombin (AT) is formed, • Higher precision potentiating its anticoagulant activity up to • Lower levels of discordant results1,2,4 1,000-fold, which inactivates both thrombin (FIIa) • Faster time to achieve therapeutic levels1,3,4 and Factor Xa (FXa). UFH acts through both FIIa 1,3,4,5 and FXa inhibition, while LMWH is a more efficient • Fewer tests and dosage changes catalyst for FXa inhibition. Direct Xa inhibitors Anticoagulation for patients with venous DOACs do not require routine monitoring. However, thromboembolism (VTE) previously included there are specific instances when an understanding heparin, heparin derivatives and/or oral vitamin K of the DOAC concentration in a patient sample may antagonists.
    [Show full text]
  • Somatropin Adult Mcp004d
    Subject: Recombinant Human Growth Hormone Original Effective Date: 7/5/2007 (somatropin)_ADULT Growth Hormone Deficiency ° GHD ° HIV/AIDS-associated wasting and cachexia ° Short Bowel Syndrome (SBS) Policy Number: Revision Date(s): 4/28/2010, 4/27/2011, MCP-004-D 3/14/2017 Review Dates: 4/28/2010, 4/27/2011, 3/14/2017, 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended to facilitate the Utilization Management process. It expresses Molina's determination as to whether certain services or supplies are medically necessary, experimental, investigational, or cosmetic for purposes of determining appropriateness of payment. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered (i.e., will be paid for by Molina) for a particular member. The member's benefit plan determines coverage. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there are any exclusion(s) or other benefit limitations applicable to this service or supply. If there is a discrepancy between this policy and a member's plan of benefits, the benefits plan will govern. In addition, coverage may be mandated by applicable legal requirements of a State, the Federal government or CMS for Medicare and Medicaid members. CMS's Coverage Database can be found on the CMS website. The coverage directive(s) and criteria from an existing National Coverage Determination (NCD) or Local Coverage Determination (LCD) will supersede the contents of this MCP document and provide the directive for all Medicare members.
    [Show full text]
  • TITLE: Tinzaparin Versus Dalteparin Or Enoxaparin for the Treatment of Venous Thromboembolism in Adults: Safety and Guidelines
    TITLE: Tinzaparin versus Dalteparin or Enoxaparin for the Treatment of Venous Thromboembolism in Adults: Safety and Guidelines DATE: 12 March 2013 RESEARCH QUESTION 1. What is the clinical evidence for the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults with a glomerular filtration rate (eGFR) less than 30 ml/min? 2. What is the clinical evidence for the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism in adults who require dialysis? 3. What are the evidence-based guidelines for the use of tinzaparin for adults with venous thromboembolism and a glomerular filtration rate less than 30 mL/min or adults who require dialysis? KEY MESSAGE Two meta-analyses, one randomized controlled trial, and one non-randomized study were identified regarding the safety of tinzaparin versus dalteparin or enoxaparin for the treatment of venous thromboembolism. No evidence-based guidelines were identified. METHODS A limited literature search was conducted on key resources including Pubmed, The Cochrane Library (2013, Issue 2), University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. No methodological filters were applied. Where possible, retrieval was limited to the human population. The search was also limited to documents published between January 1, 2003 and March 1, 2013. Internet links were provided, where available. Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews.
    [Show full text]
  • Earnings Presentation
    GOOD START INTO MerckTHE KGaA , Darmstadt,YEAR Germany, Q1 2016 results Marcus Kuhnert, CFO Belén Garijo, CEO Healthcare May 19, 2016 Disclaimer Publication of Merck KGaA, Darmstadt, Germany. In the United States and Canada the group of companies affiliated with Merck KGaA, Darmstadt, Germany operates under individual business names (EMD Serono, Millipore Sigma, EMD Performance Materials). To reflect such fact and to avoid any misconceptions of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. This version of the publication, therefore, slightly deviates from the otherwise identical version of the publication provided outside the United States and Canada. 2 Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. These forward-looking
    [Show full text]
  • What You Need to Know About Deep Vein Thrombosis (DVT)
    What You Need to Know About Deep Vein Thrombosis What is a Deep Vein Thrombosis? A deep vein thrombosis (DVT) is a blood clot that forms in the veins in the body (usually in the leg or pelvis). What causes a Deep Vein Thrombosis? Deep vein thrombosis (DVT) sometimes occurs for no apparent reason. However, certain factors can increase the chance of developing a DVT: • Inactivity • Hospital stays and surgery • Damage to your blood vessel from an injury or trauma • Medical and genetic conditions • Pregnancy • Taking estrogen-based medicine such as hormonal birth control or hormone replacement therapy • Overweight or obese • Family history of DVT • Older age What are the symptoms of DVT? Only about half of the people who have a DVT have signs and symptoms. These signs and symptoms of a deep vein clot include: • Pain or tenderness, often starting in the calf. • Swelling, including the ankle & foot. • Warmth and redness of the area or a noticeable discoloration Vascular Surgery -1- How is a DVT diagnosed? Your doctor will ask you questions about your symptoms and if your symptoms suggest that a blood clot is likely, you could have one or all of the following tests: • Blood test for a D-dimer: this test measures the level of a compound released when blood clots are dissolving. A high level may mean you have Deep Vein Thrombosis (DVT). • Imaging studies: o Ultrasound – This is the most common test for diagnosing deep vein blood clots. This test uses sound waves to create pictures of blood flowing through the arteries and veins in the affected leg.
    [Show full text]
  • What Lessons Can We Learn from 20 Years of Chemokine T D Di ? Receptor
    What lessons can we learn from 20 years of chemokine receptdtor drug discovery? John G. Cumming, PhD 5th RSC / SCI symposium on GPCRs in Medicinal Chemistry 15th-17th September 2014, Actelion, Allschwil, Basel, Switzerland Outline Background: chemokines and their receptors Chemokine receptor drug discovery and development Emerging opportunities for chemokine drug discovery Conclusions and learning Chemokines and chemokine receptors CXC(α) • Chemokines (chemoattractant cytokines) are 70-120 aa proteins • 44 chemokines in 4 major families and 22 chemokine receptors in human genome • ‘Cell positioning system’ in the body • Many receptors bind multiple ligands • Many ligands bind multiple receptors Chemotaxis Human monocytes + CCL2 (red) Volpe et al. PLoS ONE 2012, 7(5), e37208 CCR2 antagonists inhibit chemotaxis and infiltration Vasculature CCL2 release Spinal or Peripheral Tissue Recruited monocyte Site of CCL2 release CCR2 antagonists inhibit chemotaxis and infiltration CCR2 antagonist Circulating monocyte CCL2 release CCL2 release from peripheral injury site or central PAF terminals Role of chemokine system in pathophysiology • Potential role in inflammatory and autoimmune diseases: Multiple sclerosis, Rheumatoid arthritis, COPD, allergic asthma, IBD, psoriasis - Expression levels of chemokines and receptors in relevant tissues and organs of patients and animal disease models - Mouse knockout ppyphenotype in disease models • Established role in HIV infection Katschke et al., 2001 Arthritis Rheum, 44, 1022 - CCR5 and CXCR4 act as HIV-1
    [Show full text]
  • Exactus Drug List by Disease State
    Name changes, innovation continues Name changes, patient care continues Anemia ALIMTA ELOXATIN KISQALI SYLATRON ARANESP ALKERAN ELSPAR KYPROLIS SYNRIBO EPOGEN ARRANON EMPLICITI LETROZOLE TAFINLAR PROCRIT ARZERRA ERBITUX LEUCOVORIN CALCIUM TARCEVA RETACRIT AVASTIN ERIVEDGE LEUSTATIN TARGRETIN AZACITIDINE ERWINAZE LUPANETA PACK TASIGNA Anticoagulants BCG VACCINE (TICE STRAIN) ETHYOL MEKINIST TAXOTERE ARIXTRA BENDEKA ETOPOPHOS MESNA TEMODAR ENOXAPARIN SODIUM BESPONSA ETOPOSIDE MITOMYCIN TEMOZOLOMIDE FONDAPARINUX SODIUM BEXXAR FARYDAK MITOXANTRONE HCL THALOMID FRAGMIN BICNU FASLODEX MOZOBIL THIOTEPA LOVENOX BLEOMYCIN SULFATE FEMARA MUSTARGEN TOPOTECAN HCL CAMPATH FLUDARA MYLOTARG TORISEL Anti-Emetic CAMPTOSAR FOLOTYN NINLARO TREANDA AKYNZEO CAPECITABINE FUSILEV NIPENT TRELSTAR GRANISETRON HCL CARBOPLATIN GAZYVA NOVANTRONE TRETINOIN SANCUSO CERUBIDINE GEMCITABINE HCL ODOMZO TRISENOX SUSTOL CISPLATIN GEMZAR OFORTA TYKERB ONDANSETRON HCL CLADRIBINE GLEEVEC ONCASPAR VALSTAR CLOLAR HALAVEN ONTAK VANDETANIB Asthma COSMEGEN HERCEPTIN ONUREG VANTAS CINQAIR COTELLIC HYCAMTIN OPDIVO VECTIBIX DUPIXENT CYCLOPHOSPHAMIDE IDAMYCIN PFS OXALIPLATIN VELCADE XOLAIR CYTARABINE IDARUBICIN HCL PACLITAXEL VENOFER DACARBAZINE IFEX PERJETA VIDAZA Cancer/Chemotherapy DACOGEN IFOSFAMIDE PIQRAY VINCRISTINE SULFATE ABRAXANE DARZALEX IMATINIB MESYLATE POMALYST VINORELBINE TARTRATE ADCETRIS DAUNOXOME IRINOTECAN HCL PROLEUKIN VOTRIENT ADRIAMYCIN DECITABINE ISTODAX REVLIMID XELODA ADRUCIL DOCETAXEL IXEMPRA RITUXAN YERVOY AFINITOR DOXIL JEVTANA RYDAPT YONDELIS AFINITOR DISPERZ
    [Show full text]
  • Supplementary Material Table of Contents
    Supplementary M aterial Table of Contents 1 - Online S u pplementary Methods ………………………………………………...… . …2 1.1 Study population……………………………………………………………..2 1.2 Quality control and principal component analysis …………………………..2 1.3 Statistical analyses………………………………………… ………………...3 1.3.1 Disease - specific association testing ……………………………… ..3 1.3.2 Cross - phenotype meta - analysis …………………………………… .3 1.3.3 Model search ……………………………………………………… .4 1.3.4 Novelty of the variants …………………………………………… ..4 1.3.5 Functional Enrichment Analy sis ………………………………… ...4 1.3.6 Drug Target Enrichment Analysis ………………………………… 5 2 - Supplementary Figures………………………………………...………………… . …. 7 3 - Members of the Myositis Genetics Consortium (MYOGEN) ……………………. ..16 4 - Members of the Scleroderma Genetics Consortium ………………… ……………...17 5 - Supplementary References………………………………………………………… . .18 6 - Supplementary Tables………………………………………………………… . ……22 1 Online supplementary m ethods Study population This study was conducted using 12,132 affected subjects and 23 ,260 controls of European des cent population and all of them have been included in previously published GWAS as summarized in Table S1. [1 - 6] Briefly, a total of 3,255 SLE cases and 9,562 ancestry matched controls were included from six countrie s across Europe and North America (Spain, Germany, Netherlands, Italy, UK, and USA). All of the included patients were diagnosed based on the standard American College of Rheumatology (ACR) classification criteria. [7] Previously described GWAS data from 2,363 SSc cases and 5,181 ancestry
    [Show full text]
  • Innohep® Is and What It Is Used for • If You Have Kidney Problems
    Scale Get-up Material No Sent by e-maiL l 5. RBE 100% GB 066478-XX Subject Date Date 14/09/20 066478 INS 205 x 315 mm with 2 foils 27/05/20 066478-XX Colour Sign. Sign. SOP_000647, SOP_000962, SOP_000647, SOP_000962 Black OMA SOP_003993 and and SOP_008676 SOP_008676 Preparation Place of production Strength ® Packsize innohep syringe 20,000 IU/ml France Comments: Page 1 of 2 Font size: 9 pt Headings 10 pt Mock-up for reg. purpose IFR012-01 - 205 x 315 mm Page 4 of 4 Page 1 of 4 066478-XX Package leaflet: Information for the user syringe 20,000 IU/ml tinzaparin sodium Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. 066478 • If you have any further questions, ask your doctor, pharmacist or nurse. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. • In this leaflet innohep 20,000 IU/ml syringe will be called innohep. What is in this leaflet • If you have an artificial heart valve. 1. What innohep® is and what it is used for • If you have kidney problems. 2. What you need to know before you use innohep® • If you have asthma, as this medicine contains sodium 3.
    [Show full text]
  • Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management
    Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management Green-top Guideline No. 37b April 2015 Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management This is the third edition of this guideline. The first edition was published in April 2001 under the same title (numbered Green-top Guideline No. 28) and the second edition was published in February 2007 and reviewed in 2010. Thromboprophylaxis during pregnancy and the puerperium is addressed in Green-top Guideline No. 37a. Executive summary of recommendations Diagnosis of acute venous thromboembolism (VTE) How is acute VTE diagnosed in pregnancy? Any woman with symptoms and/or signs suggestive of VTE should have objective testing performed C expeditiously and treatment with low-molecular-weight heparin (LMWH) given (see section 6) until the diagnosis is excluded by objective testing, unless treatment is strongly contraindicated. Individual hospitals should have an agreed protocol for the objective diagnosis of suspected VTE during pregnancy. This may recommend the involvement of obstetricians, radiologists, physicians P and haematologists. What investigations are needed for the diagnosis of an acute DVT? Compression duplex ultrasound should be undertaken where there is clinical suspicion of DVT. B If ultrasound is negative and there is a low level of clinical suspicion, anticoagulant treatment can C be discontinued. If ultrasound is negative and a high level of clinical suspicion exists, anticoagulant treatment should be discontinued but the ultrasound should be repeated on days 3 and 7. [New 2015] What investigations are needed for the diagnosis of an acute pulmonary embolism (PE)? Women presenting with symptoms and signs of an acute PE should have an electrocardiogram C (ECG) and a chest X-ray (CXR) performed.
    [Show full text]